Zeta PD-L1 Antibody. Zeta’s recombinant rabbit antibody recognizes PD-L1 (Programmed cell death ligand 1), a protein that is overexpressed in human tumors including melanoma, diffuse large B-cell lymphoma, and carcinomas of the lung, bladder, breast, kidney and colon. Zeta’s PD-L1 antibody (clone ZR3) specifically binds PD-L1, also known as Cluster of Differentiation (CD274) or B7 homolog1 (B7-H1). PD-L1 is a type 1 transmembrane protein involved in the regulation of cellular and humoral immune responses. The interaction of PD-L1 with its receptor PD-1 provides both stimulatory and inhibitory signals in regulating T cell activation and tolerance during pregnancy, tissue allografts, autoimmune disease and malignant transformation. The binding of PD-L1 to PD-1 induces apoptosis or exhaustion in activated T cells, where blockade of this interaction has been shown to enhance the antitumor activity of T cells.
In its normal function, PD-L1 is an immune checkpoint protein that regulates the immune response to prevent chronic autoimmune inflammation and is normally expressed on activated immune cells such as antigen presenting cells and B cells. PD-L1 expression is induced in response to inflammation and high level cytokine expression, where it binds cell surface receptors PD1 and B7 on CD8+ T cells. It is believed that cancers express PD-L1 as an adaptive immune resistance mechanism to attenuate the host antitumor immune response. As a result, many therapeutic products see to block PD-L1 and PD1 acvity to reactive T cell mediated tumor cell killing.
Zeta’s PD-L1 antibody provides superior specificity and immunohistochemistry staining patterns. PD-L1 is positive in a small number of normal tissues (immune cells and tonsil) and in a large number of cancer tissues including non-small cell lung carcinoma, cervical cancer, head and neck squamous cell carcinoma, urothelial carcinoma, triple negative breast cancer, and esophageal squamous cell carcinoma. Additionally, PD-L1 is often overexpressed in placenta, and many other human tumors such as melanoma, diffuse large B-cell lymphoma, and carcinomas of the lung, bladder, breast, kidney and colon.
Antibodies to PD-L1 can provide information regarding nonsmall cell lung carcinoma (NSCLC), cervical carcinoma (including cervical squamous cell carcinoma and endocervical adenocarcinoma), urothelial carcinoma, head and neck squamous cell carcinoma (HNSCC), advanced/metastatic triple negative breast cancer (TNBC), esophageal squamous cell carcinoma (ESCC).
Visit PD-L1 LDT | NeoGenomics Laboratories for use case for ZR3, Zeta’ PD-L1 rabbit recombinant monoclonal antibody.
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.